NPD

Nanopeptide (Qingdao) Biotechnology Ltd., initiated by Professor Chen Pu, a member of the Canadian Academy of Engineering, in June 2017, focuses on applying nanotechnology to develop biopharmaceuticals. The company is committed to the research and development of internationally leading small nucleic acid precision medical products, providing targeted gene therapies and immunotherapies for cancer treatment. Additionally, it develops highly efficient and low-toxicity peptide nanoparticle drug delivery systems for the targeted treatment of various diseases. The company has published over 200 SCI academic papers.